What does this research mean for the field?

The routine analysis of non-cardiac-related drugs for QTc prolongation presents significant methodological challenges regarding outcome definition, variable selection, and statistical analysis, requiring careful methodological consideration. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

April 1, 1999The Journal of Clinical Pharmacology

Assessment of QTc Prolongation for Non‐Cardiac‐Related Drugs from a Drug Development Perspective

View Full Paper

Ask AI

Bookmark

Design

Review

Authors

PBPeter L. BonateAstellas Pharma (Japan)TRTanya L. RussellAustralian Institute of Tropical Health and Medicine

Discussion

Member takes

Implication

Urges caution interpreting QTc data for non-cardiac drugs amid methodological pitfalls; leaves open standardized statistical approaches.

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bonate et al. (1999) studied this question.

synapsesocial.com/papers/6a1be6f11567d2fc4d5f3b2a https://doi.org/10.1177/00912709922007912

View Full Paper

Ask AI

Bookmark

Assessment of QTc Prolongation for Non‐Cardiac‐Related Drugs from a Drug Development Perspective

Discussion

Member takes

Implication

Key Points

Cite This Study

Assessment of QTc Prolongation for Non‐Cardiac‐Related Drugs from a Drug Development Perspective

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider